Morbidity, mortality and cost from HPV-related oropharyngeal cancer

Impact of 2-, 4- and 9-valent vaccines

Greg Ward, Vikas Mehta, Michael Moore

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

ABSTRACT: Objective: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) related to human papillomavirus (HPV) is increasing at a dramatic rate, with men affected more commonly than women. Individuals who develop this disease suffer significant morbidity and potential mortality from their cancer and its associated treatment. We aim to evaluate the possible impact that the currently available HPV vaccines will have on this group of cancers. Data sources: Available peer-reviewed literature, practice guidelines, and statistics published by the Center for Disease Control and Prevention. Review methods: Contemporary peer-reviewed medical literature was selected based on its scientific validity and relevance to the impact HPV vaccination may have on the morbidity, mortality and cost resulting from HPV-related OPSCC in the United States. Conclusions: The incidence of HPV-related OPSCC is increasing at a near epidemic rate in the United States. The cost of treatment of HPV-related OPSCC is high, and the disease and its therapy result in significant morbidity and potential mortality to individuals. Using a cut-off of $50,000/Quality-Adjusted Life Year, expansion of current HPV vaccine indications to include prevention of OPSCC in both men and women should be recommended.

Original languageEnglish (US)
Pages (from-to)1343-1347
Number of pages5
JournalHuman Vaccines and Immunotherapeutics
Volume12
Issue number6
DOIs
StatePublished - Jun 2 2016
Externally publishedYes

Fingerprint

Oropharyngeal Neoplasms
Squamous Cell Carcinoma
Vaccines
Morbidity
Costs and Cost Analysis
Mortality
Papillomavirus Vaccines
Second Primary Neoplasms
Quality-Adjusted Life Years
Information Storage and Retrieval
Incidence
Centers for Disease Control and Prevention (U.S.)
Practice Guidelines
Health Care Costs
Vaccination
Neoplasms

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Morbidity, mortality and cost from HPV-related oropharyngeal cancer : Impact of 2-, 4- and 9-valent vaccines. / Ward, Greg; Mehta, Vikas; Moore, Michael.

In: Human Vaccines and Immunotherapeutics, Vol. 12, No. 6, 02.06.2016, p. 1343-1347.

Research output: Contribution to journalComment/debate

@article{ac3d7ae7fb79407bb1d02a738caf74b5,
title = "Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4- and 9-valent vaccines",
abstract = "ABSTRACT: Objective: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) related to human papillomavirus (HPV) is increasing at a dramatic rate, with men affected more commonly than women. Individuals who develop this disease suffer significant morbidity and potential mortality from their cancer and its associated treatment. We aim to evaluate the possible impact that the currently available HPV vaccines will have on this group of cancers. Data sources: Available peer-reviewed literature, practice guidelines, and statistics published by the Center for Disease Control and Prevention. Review methods: Contemporary peer-reviewed medical literature was selected based on its scientific validity and relevance to the impact HPV vaccination may have on the morbidity, mortality and cost resulting from HPV-related OPSCC in the United States. Conclusions: The incidence of HPV-related OPSCC is increasing at a near epidemic rate in the United States. The cost of treatment of HPV-related OPSCC is high, and the disease and its therapy result in significant morbidity and potential mortality to individuals. Using a cut-off of $50,000/Quality-Adjusted Life Year, expansion of current HPV vaccine indications to include prevention of OPSCC in both men and women should be recommended.",
author = "Greg Ward and Vikas Mehta and Michael Moore",
year = "2016",
month = "6",
day = "2",
doi = "10.1080/21645515.2015.1095415",
language = "English (US)",
volume = "12",
pages = "1343--1347",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Morbidity, mortality and cost from HPV-related oropharyngeal cancer

T2 - Impact of 2-, 4- and 9-valent vaccines

AU - Ward, Greg

AU - Mehta, Vikas

AU - Moore, Michael

PY - 2016/6/2

Y1 - 2016/6/2

N2 - ABSTRACT: Objective: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) related to human papillomavirus (HPV) is increasing at a dramatic rate, with men affected more commonly than women. Individuals who develop this disease suffer significant morbidity and potential mortality from their cancer and its associated treatment. We aim to evaluate the possible impact that the currently available HPV vaccines will have on this group of cancers. Data sources: Available peer-reviewed literature, practice guidelines, and statistics published by the Center for Disease Control and Prevention. Review methods: Contemporary peer-reviewed medical literature was selected based on its scientific validity and relevance to the impact HPV vaccination may have on the morbidity, mortality and cost resulting from HPV-related OPSCC in the United States. Conclusions: The incidence of HPV-related OPSCC is increasing at a near epidemic rate in the United States. The cost of treatment of HPV-related OPSCC is high, and the disease and its therapy result in significant morbidity and potential mortality to individuals. Using a cut-off of $50,000/Quality-Adjusted Life Year, expansion of current HPV vaccine indications to include prevention of OPSCC in both men and women should be recommended.

AB - ABSTRACT: Objective: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) related to human papillomavirus (HPV) is increasing at a dramatic rate, with men affected more commonly than women. Individuals who develop this disease suffer significant morbidity and potential mortality from their cancer and its associated treatment. We aim to evaluate the possible impact that the currently available HPV vaccines will have on this group of cancers. Data sources: Available peer-reviewed literature, practice guidelines, and statistics published by the Center for Disease Control and Prevention. Review methods: Contemporary peer-reviewed medical literature was selected based on its scientific validity and relevance to the impact HPV vaccination may have on the morbidity, mortality and cost resulting from HPV-related OPSCC in the United States. Conclusions: The incidence of HPV-related OPSCC is increasing at a near epidemic rate in the United States. The cost of treatment of HPV-related OPSCC is high, and the disease and its therapy result in significant morbidity and potential mortality to individuals. Using a cut-off of $50,000/Quality-Adjusted Life Year, expansion of current HPV vaccine indications to include prevention of OPSCC in both men and women should be recommended.

UR - http://www.scopus.com/inward/record.url?scp=84961391783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961391783&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1095415

DO - 10.1080/21645515.2015.1095415

M3 - Comment/debate

VL - 12

SP - 1343

EP - 1347

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 6

ER -